Investigational drug · Phase 2
MHB039A
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "MHB039A"
First trial start
2024
Apr 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MHB039A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Solid Tumor
- Advanced Breast Cancer
- Advanced Lung Cancer
- Advanced Solid Tumor
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MHB039A" as an intervention, largest first.
- A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung CancerRecruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07229599 · 300 participants (planned) · Start May 9, 2025 · Primary completion May 2029
Drug: MHB036C for Injection; MHB039A for Injection and 2 more · For: Advanced Lung Cancer
Sites: Shanghai, China
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07130383 · 210 participants (planned) · Start Sep 30, 2025 · Primary completion Aug 2029
Drug: MHB036C for Injection; MHB039A for Injection · For: Advanced Breast Cancer; Advanced Malignant Solid Tumor
Sites: Shanghai, China
- A Study of MHB039A for Advanced Solid TumorActive, not recruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT06345482 · 196 participants (planned) · Start Apr 16, 2024 · Primary completion Apr 1, 2028
Drug: MHB039A · For: Advanced Solid Tumor
Sites: Shanghai, China
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07126665 · 116 participants (planned) · Start Sep 18, 2025 · Primary completion Aug 2029
Drug: MHB088C for Injection; MHB039A for Injection · For: Advanced Malignant Solid Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Malignant Solid Tumor
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- PRL3-ZUMABPhase 34 trials
Intra-IMMUSG Pte Ltd · Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers
- MHB036CPhase 23 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer
- Recombinant Human IL1215-PDL1B Oncolytic HSV-1, VG161Phase 23 trials
CNBG-Virogin Biotech (Shanghai) Ltd. · Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma
- PD-L1 monoclonal antibodyPhase 22 trials
Suzhou BlueHorse Therapeutics Co., Ltd. · Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor
- SCTB39-1Phase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor
- SCTB39GPhase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor, Advanced Malignant Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.